Grounded valuation is based on a normalized EV/EBITDA multiple of ~10x on sustainable, ex-COVID EBITDA (industry range 9–12x), reflecting Gilead's high margins, recurring revenue, and robust pipeline but discounting for cell therapy headwinds and R&D risk. Share count is based on most recent report…
Gilead Sciences (GILD) Q2 2026: PrEP Sales Double, HIV Franchise Reaches $4B Run Rate
Gilead’s Q2 revealed a decisive acceleration in its HIV prevention (PrEP) business, with sales doubling and a $4 billion annual run rate now in sight. The quarter also marked notable advances in oncology and liver disease, while the company’s pipeline and recent acquisitions signal a multi-year diversification strategy. Management raised full-year guidance, citing robust commercial execution, but cell therapy and legacy revenues remain under pressure.
Summary
- PrEP Momentum Surges: HIV prevention business outpaces market, establishing new leadership benchmarks.
- Pipeline and Portfolio Expansion: Oncology and liver disease launches, plus new platform acquisitions, broaden future growth levers.
- Guidance Lift Signals Confidence: Upward revisions reflect base business strength, but cell therapy remains a drag.
Business Overview
Gilead Sciences is a global biopharma company specializing in antiviral, oncology, and liver disease therapies. The company’s revenue is anchored by its HIV franchise, encompassing both treatment and prevention (PrEP) products, with additional segments in oncology (notably Tredelvi), liver disease (Livdelzy, Hepcludex), and cell therapy (Kite). Gilead monetizes its portfolio through branded drug sales, with expanding contributions from newly launched and pipeline products.
Performance Analysis
Q2 delivered a step-change in Gilead’s base business growth, led by HIV and PrEP. Excluding COVID-related Veclury, total product sales reached $7.6 billion, up 10% year-over-year, with HIV contributing $5.7 billion and PrEP sales surpassing $1 billion for the first time in a quarter. Biktarvy, the leading HIV treatment, grew 7% YoY, while PrEP products Yes2Go and Descovy posted sequential and YoY gains far above market rates. Oncology also contributed, with Tredelvi up 26% YoY, driven by expanded indications in breast cancer. Liver disease sales were up 10% YoY, fueled by Livdelzy’s momentum.
Cell therapy was the lone weak spot, declining 14% YoY, a function of competitive pressures and market dynamics. Gross margin held steady at 87%, with higher SG&A tied to PrEP launches. The quarter’s reported loss stemmed from $11.2 billion in acquired R&D, masking underlying EPS growth of 13% (excluding M&A impacts). Management raised full-year sales and EPS guidance, reflecting confidence in core franchises.
- PrEP Outpaces Market Expansion: Yes2Go and Descovy for PrEP grew at over twice the U.S. market rate, with persistency rates above 70% for injectables.
- Oncology Launches Gain Traction: Tredelvi’s new indications nearly double its addressable population, supporting durable growth in metastatic breast cancer.
- Liver Disease Franchise Accelerates: Livdelzy sales more than doubled YoY, while Hepcludex launch addresses an underserved hepatitis delta population.
Gilead’s diversified momentum is visible in both top-line and pipeline progress, but cell therapy and COVID-related sales remain headwinds. The company’s raised guidance underscores management’s confidence in continued execution.
Executive Commentary
"Quarterly PrEP sales doubled year-over-year, exceeding $1 billion for the first time. With a $4 billion annual run rate for our PrEP business and Biktarvy's continued strength, we are raising our full-year HIV growth expectations to 9% to 10% year-over-year from prior guidance of 8% growth."
Daniel O'Day, Chairman and Chief Executive Officer
"Our base business grew 10% year over year to $7.6 billion, driven by continued growth across HIV products, Tredelvi and Livdelzi, partially offset by lower sales of cell therapy and HCV products."
Andrew Dickinson, Chief Financial Officer
Strategic Positioning
1. HIV Franchise: Market Leadership and Product Optionality
Gilead’s HIV business remains the company’s economic engine, but leadership is now defined by both treatment and prevention. The launch of Yes2Go, a long-acting injectable PrEP, and the anticipated BicLen (Bictegravir + Lenacapavir) oral regimen, alongside a robust pipeline of weekly, monthly, and yearly treatment options, position Gilead to defend and expand its market share as patient preferences shift. Optionality in dosing and modality is a clear differentiator, supporting both switch and naive markets.
2. Oncology Expansion: ADCs and Tredelvi Platform
Oncology is emerging as a core diversification pillar. Tredelvi’s expanded label in first-line metastatic triple-negative breast cancer (TNBC) nearly doubles its eligible patient pool. The Tubulus acquisition adds an antibody-drug conjugate (ADC) platform and promising clinical assets, such as GS8824, with early efficacy signals in ovarian cancer, setting up future registration studies. Gilead is investing in both breadth (new targets, new platforms) and depth (label expansion, guideline inclusion).
3. Liver Disease: New Launches and Pipeline Read-Through
Livdelzy’s rapid adoption in primary biliary cholangitis (PBC) and the U.S. launch of Hepcludex for hepatitis delta demonstrate Gilead’s ability to leverage its commercial infrastructure in underpenetrated liver disease segments. Positive Phase III data and ongoing label expansion efforts point to sustained growth, albeit off a smaller base than HIV or oncology.
4. Cell Therapy: Integration and Competitive Pressures
Cell therapy (Kite) remains challenged by in-class competition and market access friction, with sales down 14% YoY. The Arcelix acquisition gives Gilead full ownership of NitoCell (multiple myeloma), enabling faster execution, but near-term growth is muted. The D-domain binder platform and in vivo CAR-T development could unlock future value, but require execution and regulatory clarity.
5. M&A and Capital Allocation Discipline
Recent acquisitions (Arcelix, Tubulus, Oro Medicines) signal a strategic pivot toward innovation platforms, but management emphasized integration and operational focus for the remainder of 2026. Shareholder returns remain robust, with nearly half of free cash flow returned in H1 via dividends and buybacks. Management is not planning further large M&A in the near term, prioritizing internal pipeline advancement.
Key Considerations
Q2 marks a clear inflection in Gilead’s commercial and clinical trajectory, with HIV, oncology, and liver disease all contributing to growth. The company’s ability to execute multiple launches, integrate acquisitions, and maintain margin discipline will be central to sustaining this momentum.
Key Considerations:
- HIV Franchise Durability: Patient and physician demand for long-acting and weekly options supports both market expansion and share defense.
- Oncology Platform Leverage: ADC and cell therapy investments seek to replicate Tredelvi’s commercial success in new indications and tumor types.
- Pipeline Execution Risk: Multiple late-stage readouts and launches are scheduled for 2027 and beyond, requiring flawless operational delivery.
- Competitive and Payer Dynamics: Cell therapy and HIV treatment face reimbursement and access headwinds, particularly as market shifts and ACA changes impact volumes.
Risks
Gilead’s near-term risks center on competitive pressures in cell therapy, payer-driven volume shifts in HIV treatment, and the integration of recent acquisitions. Regulatory uncertainty around CAR-T approval pathways and evolving PrEP market preferences could impact future growth. The company’s reliance on its HIV franchise, while diversified by new modalities, remains a concentration risk if market dynamics shift unexpectedly.
Forward Outlook
For Q3 2026, Gilead guided to:
- Continued double-digit growth in base business, led by HIV and PrEP.
- Sequential improvement in oncology and liver disease, with new launches gaining traction.
For full-year 2026, management raised guidance:
- Base business sales of $29.8–$30.1 billion (up from prior midpoint by $350 million).
- HIV sales growth of 9–10% (up from 8%), with PrEP at a $4 billion run rate.
Management cited “another two commercial launches in HIV and oncology” for the second half, ongoing integration of new platforms, and a focus on clinical milestones as key drivers.
- Expanded pipeline catalysts in 2027 and beyond.
- Integration of recent M&A prioritized over new deals in the near term.
Takeaways
Gilead’s Q2 2026 results confirm a multi-year growth inflection, driven by PrEP leadership, oncology expansion, and pipeline depth. The company’s ability to sustain commercial momentum while integrating new platforms will be critical to long-term value creation.
- PrEP and HIV Optionality Lead Growth: Commercial execution and product innovation have positioned Gilead to extend its HIV leadership well into the next decade.
- Oncology and Liver Disease Diversify Revenue Streams: Tredelvi and Livdelzy launches validate the company’s ability to execute beyond HIV, but scale remains in progress.
- Pipeline and Integration Execution Are Key Watchpoints: Investors should monitor the cadence of late-stage readouts, launch uptake, and cell therapy turnaround as signals of durable growth.
Conclusion
Gilead’s second quarter underscores its transition from HIV-centricity to a multi-franchise growth story, with PrEP, oncology, and liver disease each contributing to a broader, more resilient portfolio. Sustained execution across launches and pipeline milestones will determine whether this momentum translates into long-term shareholder value.
Industry Read-Through
Gilead’s PrEP surge and product diversification highlight a broader industry pivot toward long-acting and flexible dosing regimens, raising the bar for HIV competitors and reinforcing the value of patient-centric innovation. The oncology ADC and cell therapy platforms signal intensifying competition in next-generation cancer therapies, with Gilead’s acquisitions underscoring the premium placed on pipeline breadth and platform scalability. For the sector, payer and regulatory dynamics—especially in cell therapy and prevention markets—remain critical variables shaping future growth trajectories.